4 takeaways from Tuesday’s Senate drug pricing hearing
Seven pharma executives were grilled on drug prices on Capitol Hill on Tuesday.
Regulatory
Live blog: Pharma execs on the Hill
The latest from the Senate Finance Committee’s grilling of pharma executives on Capitol Hill.
What to watch: Congress to grill pharma CEOs over drug prices Tuesday
Seven top pharma executives are set to testify in front of lawmakers.
Was President Trump’s plan to reduce drug prices DOA?
President Trump’s blueprint to lower drug prices hasn’t made it out of the brainstorm phase.
Texas ACA ruling could reverberate across healthcare
Texas Judge Reed O’Connor’s ruling on the ACA could affect both insurers and pharma.
Democrats could make drug pricing deal with President Trump
Many midterm winners campaigned on bringing down prices, and experts predict the issue to remain top of mind.
How the pharma industry may be impacted by drug pricing and other policies in 2019
Now that the political climate lends itself to action on drug pricing, the days of pharma nirvana may be coming to an end. Here’s a look at the policy considerations likely to vex the industry in the year ahead.
Karen Newmark named Point of Care Communications Council executive director
Newmark said she is prioritizing working with industry stakeholders on verification and validation standards.
Democratic senator: Constituents want bipartisanship, healthcare transparency
Sen. Christopher Coons (D-DE) talked healthcare priorities at the Coalition for Healthcare Communication post-election conference in Washington D.C. on Monday.
Brodeur Partners’ Lauren Levinson on transparency in healthcare proposals
With greater transparency of the cost and sale price of a drug must also come greater transparency of the inputs, ecosystem, and risk investment on which drug development relies.
Want to read more?
Please login or register first to view this content.
